Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Welcome and Introduction to Vi3C

Opening Session Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Opening Session Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

Predicting Future Breast Cancer Outcomes Efficacy of a Polygenic Risk Score

Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO